• 8:30 - 18:00 M-T / 8.30 - 15.00 F

Bonecure


ASC pre-differentiated to osteoblasts in Histobone scaffold (engineered synthetic bone substitute) for the treatment of bone defects caused by pseudoarthrosis, infections, resections, trauma).
salvat
hc016-spine

Innovation

Regenerative capabilities of cells.

Guided osseous re-modelling process due to scaffold properties.

Excellent integration of newly formed tissue with surrounding tissue.

Adequate revascularisation.

Development stage

Clinical Phase II ongoing Q2 2018 with allogenic product.

Licensing & co-development agreement with Salvat.

2017: 6 patients treated with Bonecure autologous product and medical discharged as bone consolidation has been achieved.

2018-2019: Bonecure allogenic product clinical trial on-going with 5 patients treated.

Histocell

Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com
www.histocell.com

Our values

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell